This page shows the latest renal disease news and features for those working in and with pharma, biotech and healthcare.
And when patients cannot pay for their kidney transplants, or the waiting list for end-stage renal disease patients is so long that they die waiting for a transplant, they have
Amgen's chronic kidney disease drug Parsabiv cleared in US. Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years. ... However, some have warned that there could be pushback resulting from tighter reimbursement rules
At the same time, kidney transplantation is the treatment of choice for a growing number of patients with end-stage renal disease.
Amicus Therapeutics' Galafold (migalastat) has also received the go-ahead, and has been sanctioned by the SMC for the treatment of adults with Fabry disease, an incurable inherited genetic disorder. ... greater enzyme activity after evidence of renal,
Patients who are at high risk of repeat cardiovascular events are often older, with evidence of multi-vessel coronary artery disease, chronic non-end-stage renal dysfunction or diabetes mellitus. ... In order to achieve this the firm is working on new
Keryx Biopharmaceuticals' Fexeric approved in EU. New treatment option for chronic kidney disease. ... the reach of ferric citrate to treat patients with renal disease.”. “
More from news
Approximately 1 fully matching, plus 54 partially matching documents found.
Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS
386. AstraZeneca. Perrigo. Acquisition - asset. Entocort (budesonide) marketed for mild to moderate Crohn's disease. ... Option to license. 175. Idera Pharmaceuticals. GlaxoSmithKline. Licence, collaboration. Antisence platform for selected targets in
Stroke: Risk is up to four times higher with diabetes. Cardiovascular disease: Risk is up to four times higher with diabetes. ... Diabetic nephropathy: This is the leading cause of end-stage renal disease.
Company acquisition. Rare disease company with marketed products in US (Chenodal to treat CTX. ... 12. 1. Co-promotion rights in US. 2. Endstage renal disease. 3.
548. Cytori/Lorem. Vascular. Licence. Cell therapy for CVS, diabetes, and renal disease. ... 152. Calidus / Amicus. Acquisition. Purchase of Callidus' late-stage enzyme replacement therapy for Pompe disease.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Unsurprisingly, certain chronic conditions— like rheumatologic conditions, renal disease, diabetes, and AIDS— are associated with persistent high, long-term healthcare spending.
Mimpara is approved for the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy, and it was for this indication that the
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...